DARPA Protean Seeks Chemical Defense Breakthroughs — Abstracts Due March 12
March 7, 2026 · 2 min read
Jared Klein
DARPA's Biological Technologies Office has released Protean (solicitation DARPARA2601), a research program seeking fundamentally new approaches to protecting the human body against chemical threats. Gate 1 abstract submissions close March 12 — five days from now.
The Problem: Current Antidotes React After the Damage Starts
Existing countermeasures against chemical weapons — nerve agents, synthetic opioids, ion channel toxins — work by blocking or neutralizing the threat agent after it has already begun disrupting critical proteins. DARPA wants something different: interventions that modify the target proteins themselves, making them resistant to attack before exposure occurs.
The program targets three specific threat categories:
- Nerve agents attacking acetylcholinesterase
- Synthetic opioids targeting the mu opioid receptor
- Ion channel toxins disrupting neural signaling
Successful teams must hit concrete milestones: a 10-fold decrease in threat simulant binding affinity by Month 12, and ultimately a 10,000-fold increase in effective dose in rodent models.
Two Phases, 33 Months, Measurable Outcomes
Protean runs 33 months across two phases. Phase 1 (18 months) focuses on discovering novel regulatory sites on target proteins and demonstrating proof of concept. Phase 2 (15 months) optimizes drug design and pushes toward in vivo validation.
Awards are structured as cooperative agreements or Other Transaction contracts. DARPA has not disclosed maximum funding levels — amounts depend on proposal quality and available appropriations. Both phases must be proposed together.
Gate 1 Is Lean: Video, Five Pages, Cost Estimate
The abstract submission is compact by federal standards: a 10-minute video presentation, a five-page technical volume, and a cost estimate. Full proposals (Gate 2) are due May 7, 2026.
Eligibility is broad — U.S. and non-U.S. sources can submit, though SAM registration with a valid Unique Entity ID is required. FFRDCs and government entities should contact the program office before submitting.
Biochemistry and pharmacology teams with expertise in protein engineering, allosteric modulation, or computational drug design should act immediately given the March 12 deadline. For researchers tracking the full landscape of DARPA and defense research funding, more analysis is available on the Granted blog.